Zhu Mengliu, Chen Li, Kong Xiangyi, Wang Xiangyu, Fang Yi, Li Xingrui, Wang Jing
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Front Mol Biosci. 2022 Feb 28;9:856064. doi: 10.3389/fmolb.2022.856064. eCollection 2022.
There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not in our center between January 1998 and December 2016. Optimal SIRI threshold values were determined using the receiver operating characteristic curve (ROC). Patients were then reclassified as SIRI ≥0.80 group (High SIRI group) and SIRI <0.80 group (Low SIRI group). The outcomes were analyzed by statistical methods. The univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer. The disease-free survival (DFS) and overall survival (OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores (41.50 vs. 37.63 months, and 64.57 vs. 58.42 months). Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer, advanced breast cancer, or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI levels (2 = 2.379, = 0.123, and 2 = 5.153, = 0.023; 2 = 11.080, = 0.0009 and 2 = 15.900, < 0.0001; 2 = 16.020, < 0.0001 and 2 = 22.050, < 0.0001, respectively). SIRI serves as an easily accessible, replicable, and minimally invasive prognostic tool in breast cancer patients. Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients. SIRI may serve as a marker to guide clinical management and prognostication of breast cancer.
炎症细胞与肿瘤之间存在密切关系，但连接二者的途径仍不清楚。本研究探讨全身炎症反应指数（SIRI）在乳腺癌患者中的临床及预后价值。该研究纳入了1998年1月至2016年12月期间在本中心接受新辅助化疗的477例乳腺癌患者以及未接受新辅助化疗的308例乳腺癌患者。使用受试者工作特征曲线（ROC）确定最佳SIRI阈值。然后将患者重新分类为SIRI≥0.80组（高SIRI组）和SIRI<0.80组（低SIRI组）。采用统计学方法分析结果。单因素和多因素分析表明，SIRI可独立预测乳腺癌患者的生存情况。与高SIRI评分患者相比，低SIRI评分患者的无病生存期（DFS）和总生存期（OS）显著更长（分别为41.50个月对37.63个月，以及64.57个月对58.42个月）。进一步的亚组分析显示，与高SIRI水平患者相比，低SIRI评分且患有早期乳腺癌、晚期乳腺癌或不同分子亚型的患者的DFS和OS平均生存时间也更长（χ² = 2.379，P = 0.123，以及χ² = 5.153，P = 0.023；χ² = 11.080，P = 0.0009以及χ² = 15.900，P < 0.0001；χ² = 16.020，P < 0.0001以及χ² = 22.050，P < 0.0001）。SIRI是一种易于获取、可重复且微创的乳腺癌患者预后工具。较低的SIRI评分预示着乳腺癌患者术后更长的DFS和OS。SIRI可作为指导乳腺癌临床管理和预后评估的标志物。
Cancer Manag Res. 2022-2-25
Arq Bras Cardiol. 2024-11
Risk Manag Healthc Policy. 2021-6-21
Otolaryngol Head Neck Surg. 2022-1
Zotero 插件
